AI in Pathology Market Size, Share & Trends Analysis Report By Offering (Hardware, Software, Services), By Technology (Machine Learning, Computer Vision-based Image Analysis, Natural Language Processing), By Application (Drug Discovery, Disease Diagnosis & Prognosis, Training & Education), By End Use (Pharmaceutical & Biotechnology Companies, Hospital & Reference Laboratories, Academic & Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

AI in Pathology Market Size

The global AI in pathology market size was valued at USD 166.41 million in 2025 and is projected to grow from USD 206.02 million in 2026 to USD 1136.75 million by 2034, registering a CAGR of 23.8% during the forecast period from 2026 to 2034. North America dominated the AI in pathology market with a market share of 41.29% in 2025.

Offering Insights

The software segment accounted for the largest AI in pathology market share in 2025, as it reduces workload, interprets complex data, and simplifies lab operations. Additionally, advanced software that can detect tissue anomalies is increasingly used by academic and research organizations to speed up the research process, which, in turn, boosts the demand for software and supports segment growth.

The hardware segment is projected to be the fastest-growing segment with a CAGR of 25.16% during the forecast timeframe. Growth is propelled by the rising demand for high-resolution digital pathology scanners. These scanners provide clearer images, faster processing, and support AI analysis. Due to these advantages, hospitals and laboratories are increasingly adopting hardware for diagnostic imaging.

Request Customizationto receive a tailored report.

Technology Insights

The machine learning segment dominated the market, with a considerable share of 44.86% in 2025. Machine learning is increasingly used to address soaring diagnostic workloads and reduce inter-observer variability. Machine learning automates cell counting and tumor quantification in complex diagnosis processes, which ensures its stable demand and reinforces the dominance of the segment.

The computer vision-based image analysis segment is projected to grow at the fastest pace with a CAGR of 24.17% during 2026-2034. This growth is stimulated due to the use of AI models for automation of the quantification of histopathological features, such as nuclear morphology, which were time-consuming for humans to quantify. These vision algorithms enhance the detection of rare cancers and biomarkers, improving diagnostic consistency and accelerating research in oncology.

Application Insights

The disease diagnosis & prognosis segment dominated the market in 2025 because AI pathology tools show high diagnostic accuracy in clinical studies, with a sensitivity of about 96.3% and specificity of 93.3% when applied to whole slide images across various diseases.

The drug discovery segment is projected to grow at a CAGR of 24.42% during the forecast timeframe, as these tools help identify therapeutic targets and biomarker discovery. These capabilities help researchers analyze large pathology datasets in preclinical research. Thus, all aforementioned factors support the segment growth.

End Use Insights

The pharmaceutical & biotechnology companies segment dominated the market in 2025, because they use AI for accelerated drug discovery to analyze a high volume of tissue samples rapidly. They also utilize biomarker identification for precise and personalized therapies by using integrated solutions.

The hospital & reference laboratories segment is projected to grow at a CAGR of 24.71% during 2026-2034. These facilities handle the largest volume of pathology cases, which leads to increased AI adoption for faster and precise processing of samples.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The AI in pathology market in North America held a market share of 41.29% in 2025, which was supported by large-scale pathology digitization. For instance, the Mayo Clinic has scanned over 12 million glass slides and holds an archive of over 25 million samples. This digitization effort creates a resource for training AI models and the rapid adoption of AI pathology solutions in regional healthcare systems. The region also has a robust healthcare infrastructure and a willingness to adopt AI models.

The US dominated the region with major AI in the pathology market share, due to the early adoption of AI platforms by major clinical laboratories. For instance, PathAI’s AISight is used by over a dozen leading anatomic pathology labs to analyze complex cancer biomarkers in real patient samples. This deployment improves diagnostic precision and accelerates clinical integration across US healthcare systems.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific

The Asia Pacific market is expected to grow at a CAGR of 25.69% during the forecast period, owing to the implementation of AI-integrated digital pathology platforms in major regional hospitals. For instance, the Kameda Medical Center in Japan is digitizing workflows to enable remote tissue image review and improve diagnostic collaboration and operational efficiency.

China dominated the market in Asia Pacific due to the increasing burden of diseases, the structural shortage of trained pathologists outside urban areas, and strong government backing for AI adoption. The country is facing a high incidence of cancer, projected to reach 3.2 million by 2030 in older adults, as per PubMed. This will also lead to increasing diagnostic volume wherein AI can accelerate identification and validation on large datasets. Shortage of pathologists will also lead to higher demand of AI in pathology to streamline pre-screening and quality control outside Tier I cities. National health strategies, such as the Healthy China 2030 Plan, support the adoption of AI in healthcare facilities.

Europe

The Europe AI in pathology market is driven by higher clinical adoption of AI tools. For instance, Aiforia’s algorithms are used in routine diagnostic workflows at major French and Swedish hospitals. The adoption of AI tools assists prostate, breast, and other cancer analyses, improving diagnostic consistency. Digital health initiatives such as the EU Cancer Plan & European Health Data Space promote digital health infrastructure and cross-border data sharing. The CE-IVDR also provides clear regulations for AI-based solutions, which encourage companies to develop clinically validated AI in pathology tools.

Germany leads the Europe region due to an aging population, higher adoption of digital pathology, and a strong R&D ecosystem. It is projected that by 2030, 1 in 4 Germans will be over 60 years of age, which will increase disease burden as well as pathology workload. The country is one of the highest adopters of whole-slide imaging in the region, with integrated imaging systems in hospitals for tumor detection, biomarker quantification, and workflow automation. The country also boasts of a strong R&D ecosystem with a mix of academia, biotech, and MedTech startups.

Latin America

The Latin America AI in pathology market growth is augmented by increasing investments by established players, such as PathAI’s investment in Rede D’Or (Brazil) and Aiforia’s investments in private hospitals of Chile and Mexico. Countries in this region are also promoting digital AI healthcare tools, which reduce adoption barriers and gives boosts to pilot projects. The region has active oncology research programs, which need AI support for clinical validation and research-grade analysis. Thus, an encouraging research ecosystem and investments in AI tool integration are expected to boost the Latin American market.

Argentina is expected to lead the market in Latin America. The country has deployed platforms such as Digpatho from Córdoba, which aids rapid and consistent breast cancer detection. Active oncology research groups such as GAICO (Grupo Argentino de Investigación Clínica en Oncología) also use AI for translation research in cancer. Hospitals and private diagnostic centers are digitizing pathology operations for faster diagnosis and treatment guidance.

Middle East and Africa

The Middle East and Africa AI in pathology market is growing at a steady pace due to factors such as higher cancer incidence, a shortage of qualified professionals, and favorable government initiatives. According to Globocan 2025, the region is expected to see over 1 million new cancer cases annually due to aging populations and lifestyle changes. Thus, higher diagnostic demand will lead to higher adoption of AI in pathology for accurate and timely diagnosis. The region is facing a critical shortage of trained and seasoned pathologists, which increases dependence on AI in pathology tools to overcome diagnostic bottlenecks. Favorable government initiatives such as Vision 2030 and the UAE National AI Strategy encourage AI in healthcare and research with support in terms of funding, incentives, and policies.

The South African market is overseeing increasing healthcare demand, digital adoption, and investments in upgrading infrastructure. The country is expanding its AI integration into hospitals for remote consultation in underserved areas and reducing pathology workload. The government supports the deployment of AI and digital pathology through pilot projects in urban areas under the Pan-African Telepathology & AI Networks initiative. Global market players, such as Philips and Paige, have also entered South Africa, which will boost the deployment of cloud-based AI tools in healthcare.

Competitive Landscape

The market is moderately competitive, with established digital pathology and AI solution providers holding substantial AI in the pathology market share. Leading players such as PathAI, Paige AI, and Roche Diagnostics dominate through advanced technology platforms, extensive clinical collaborations, and strong regulatory compliance. These companies focus on product innovations, partnerships with hospitals and laboratories, and strategic integration to enhance market presence.

List of Key and Emerging Players in AI in Pathology Market